Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue (Tables)

Revenue (Tables)

12 Months Ended

Dec. 31, 2019

Revenue from Contract with Customer [Abstract]

During the years ended December 31, 2019 and 2018, respectively, the Company recognized revenues as follows (in thousands):



	Years Ended December 31,
	2019		2018
Revenue from contract with customers	$	43,646	$	27,248
Collaboration revenue	2,633		1,762
Other revenues	—		91
Total Revenue	$	46,279	$	29,101

During the years ended December 31, 2019 and 2018, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):



	Years Ended December 31,
	2019		2018
AstraZeneca	$	25,828	$	17,632
Seattle Genetics	2,493		5,413
Servier	15,048		4,508
Other	2,910		1,548
Total Revenue	$	46,279	$	29,101

Schedule of Potential Milestone Payments

Under the Company´s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions):



	Research, Development, Regulatory & Commercial Milestones		Sales Milestones
AstraZeneca	$	1,111	$	960
Servier	799		707
Seattle Genetics	769		450
Total potential milestone payments	$	2,679	$	2,117